Meet Your Oncologist

Dr. Harish Kancharla

Senior Consultant – Medical Oncology & Hemato-Oncology — Yashoda Hospitals, Somajiguda, Hyderabad

National Medical Commission (NMC) Reg. No. 77186

Dr. Harish Kancharla is a Senior Consultant in Medical Oncology and Hemato-Oncology at Yashoda Hospitals, Somajiguda, Hyderabad. He treats the full range of adult cancers — solid tumours and blood cancers alike — with a focus on accurate diagnosis, evidence-based treatment planning, and clear guidance for patients and their families.

He completed his DM in Medical Oncology at BRAIRCH, All India Institute of Medical Sciences (AIIMS), New Delhi — one of India's foremost cancer centres — after an MD in Internal Medicine at PGIMER, Chandigarh, and his MBBS at Gandhi Medical College, Hyderabad. This training across internal medicine and oncology underpins a careful, whole-patient approach to complex cancer care.

Alongside common cancers, Dr. Kancharla has a particular interest in rare and difficult-to-treat cancers — including adrenocortical carcinoma — where experience, correct treatment sequencing and multidisciplinary coordination make a real difference to outcomes. He offers both in-person consultations in Hyderabad and online second opinions for patients across India and abroad.

Education & Qualifications

• DM, Medical Oncology — BRAIRCH, All India Institute of Medical Sciences (AIIMS), Delhi
• MD, Internal Medicine — PGIMER, Chandigarh
• MBBS — Gandhi Medical College, Hyderabad, Telangana

Work Experience

• May 2021 – Present Senior Consultant, Medical Oncology & Hemato-Oncology, Yashoda Hospitals, Somajiguda, Hyderabad
• Jul 2020 – May 2021 Consultant, Medical Oncology & Hemato-Oncology, Cancer Clinics
• Sep 2016 – Jul 2020 Senior Residency, Medical Oncology, BRAIRCH, All India Institute of Medical Sciences (AIIMS), Delhi
• Jan 2016 – Sep 2016 Senior Residency, Internal Medicine, PGIMER, Chandigarh

Areas of Focus

• Breast, lung, colorectal, ovarian and head & neck cancers
• Blood cancers — leukemia, lymphoma and multiple myeloma
• Rare cancers, including adrenocortical carcinoma
• Precision oncology, chemotherapy, immunotherapy and targeted therapy
• Independent second opinions and treatment planning